Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 12
Semaglutide significantly reduced the risk of major
cardiovascular events with 26% vs placebo in SUSTAIN 6
Semaglutide demonstrated 26% reduction in
composite CV outcome compared with placebo
Patients with an
event (%)
15
10
10
5
0
0 8
semaglutide
Hazard ratio = 0.74 (95% CI: 0.58;0.95)
Events: 108 semaglutide; 146 placebo
p<0.001 for non-inferiority
p=0.02 for superiority*
placebo
•
16 24 32 40 48 56 64 72 80 88 96 104
•
•
Key results and next step
Non-inferiority of semaglutide compared to placebo was
confirmed for time to first MACE in people with type 2
diabetes
Semaglutide reduced the risk of MACE by 26% driven
by reductions of non-fatal stroke by 39%* and non-fatal MI
by 26%
Semaglutide significantly reduced the risk of nephropathy
while increasing the risk of retinopathy complications
Next step: Novo Nordisk expect to submit an NDA for
semaglutide to regulatory authorities in Q4 2016
Weeks
Note: p-value is two-sided, pooled data reported for both semaglutide and placebo
MACE: Major adverse cardiovascular event; 3-point MACE comprises cardiovascular death, non-fatal
myocardial infarction and non-fatal stroke; CI: Confidence interval
*No adjustment for multiple tests
*P-value <0.001
NDA: New drug application
novo nordiskView entire presentation